Get the Stockscreener App
3.92
1.51%
-0.06
Polypid Ltd stock is traded at $3.92, with a volume of 45,916.
It is down -1.51% in the last 24 hours and up +4.53% over the past month.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
See More
Previous Close:
$3.98
Open:
$3.97
24h Volume:
45,916
Relative Volume:
0.59
Market Cap:
$65.21M
Revenue:
-
Net Income/Loss:
$-23.87M
P/E Ratio:
-0.1993
EPS:
-19.67
Net Cash Flow:
$-47.63M
1W Performance:
-1.26%
1M Performance:
+4.53%
6M Performance:
+14.29%
1Y Performance:
+51.94%
1-Day Range:
$3.915
$4.05
1-Week Range:
$3.915
$4.07
52-Week Range:
$2.30
$4.07
Polypid Ltd Stock (PYPD) Company Profile
Compare PYPD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.92 | 66.21M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Initiated | Roth Capital | Buy |
| Jun-02-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Sep-14-21 | Initiated | JMP Securities | Mkt Outperform |
| Jul-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-24-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-10-20 | Initiated | Alliance Global Partners | Buy |
| Jul-21-20 | Initiated | BMO Capital Markets | Outperform |
| Jul-21-20 | Initiated | Barclays | Overweight |
| Jul-21-20 | Initiated | Raymond James | Outperform |
View All
Polypid Ltd Stock (PYPD) Latest News
PYPD: D-PLEX100 shows strong efficacy and safety for SSI prevention, with FDA filing planned for 2026 - TradingView — Track All Markets
PolyPid Ltd. (NASDAQ:PYPD) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing (NASDAQ: PYPD) - TradingView — Track All Markets
PolyPid receives FDA support for D-PLEX100 NDA submission By Investing.com - Investing.com Australia
PolyPid Soars 3.4% on Pivotal FDA Endorsement for D-PLEX100 NDA - Markets Financial Content
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 - Investing.com Nigeria
PolyPid stock rises after FDA supports NDA submission for D-PLEX100 By Investing.com - Investing.com South Africa
PolyPid receives FDA support for D-PLEX100 NDA submission - Investing.com
PolyPid Ltd. Announces Positive Fda Pre-Nda Meeting Minutes for D-Plex100 Supporting Nda Submission - marketscreener.com
Polypid announces positive FDA Pre-NDA meeting minutes - marketscreener.com
PolyPid Gains FDA Support for D-PLEX100 NDA Submission - TipRanks
PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission - TipRanks
PolyPid (NASDAQ: PYPD) highlights positive FDA pre-NDA minutes for D-PLEX100 NDA path - Stock Titan
Polypid Announces Positive FDA Pre-NDA Meeting Minutes - TradingView — Track All Markets
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission - GlobeNewswire
How institutional buying supports PolyPid Ltd. stockExit Point & Expert Approved Momentum Ideas - Newser
PolyPid stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
PolyPid stock rating reiterated at Market Outperform by Citizens By Investing.com - Investing.com India
Why PolyPid Ltd. stock could see breakout soonWeekly Gains Summary & Weekly Breakout Watchlists - moha.gov.vn
PolyPid Expands Share Offering to Strengthen Financial Position - TipRanks
PYPD ups at-the-market ordinary share program limit to $15M - Stock Titan
PolyPid (PYPD) raises ordinary share Sales Agreement capacity - Stock Titan
PolyPid Ltd. to Host Virtual KOL Event on D-PLEX100 and Surgical Site Infection Prevention - Quiver Quantitative
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 - Sahm
How analysts rate PolyPid Ltd. stock todayJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
What makes PolyPid Ltd. stock attractive to growth fundsJuly 2025 Setups & Trade Opportunity Analysis Reports - newser.com
Top chart patterns to watch in PolyPid Ltd.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
PolyPid price target lowered to $9 from $10 at Roth Capital - MSN
Published on: 2025-11-19 04:16:34 - newser.com
Will PolyPid Ltd. stock outperform growth indexesJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Will PolyPid Ltd. rebound enough to break evenInsider Selling & Intraday High Probability Alerts - newser.com
Why PolyPid Ltd. stock could benefit from AI revolutionMarket Movement Recap & Risk Controlled Swing Trade Alerts - newser.com
What analysts say about PolyPid Ltd stockLong-Term Growth Stocks & Start Small. End Wealthy. - earlytimes.in
FY2025 Earnings Forecast for PolyPid Issued By HC Wainwright - MarketBeat
Roth Capital Issues Optimistic Estimate for PolyPid Earnings - Defense World
Published on: 2025-11-16 12:50:26 - newser.com
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - Defense World
PolyPid Ltd. (NASDAQ:PYPD) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Polypid Ltd Stock (PYPD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):